24/7 BIOPHARMA - issue 1 / October 2024

INTERVIEW

CEO Adragos Pharma Chairman YPO Board Member MedTech space

Andreas is a scientist by background, holding a Ph.D. in Biomedicine, awarded jointly by Imperial College London and EMBL Heidelberg, where he graduated summa cum laude. He also holds an M.Sc. in Cancer Research from the Max Planck Institute and the University of Freiburg. Early in his career, Andreas transitioned from academia to industry, spending several years as entrepreneur and consultant at McKinsey & Company, where he worked across Europe, the U.S., and Asia, advising clients within the pharmaceutical and aerospace industries. He later took on top management roles in leading pharmaceutical companies, where he streamlined operations, led mergers & acquisitions, and oversaw R&D efforts. Currently, Andreas is the CEO of Adragos Pharma, a multinational CDMO with a strong footprint in Europe and Japan. He established Adragos to become a customer-centric leader in value-added generics, with expertise ranging from formulation to manufacturing across diverse dosage forms.

52 TWENTYFOURSEVENBIOPHARMA Issue 1 / October 2024